Over the years, the treatment paradigm for metastatic RCC has evolved from cytokine-based therapies to vascular endothelial growth factor-targeting agents, to mTOR-inhibitors, tyrosine kinase inhibitors, and most recently, immune checkpoint inhibitors (ICIs) have become the mainstay treatment [6,7]. Here, MTOR is linked to renal cell carcinoma.